Iguratimod
- CAS No.
- 123663-49-0
- Chemical Name:
- Iguratimod
- Synonyms
- N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide;T 614;CS-1961;IGURATIMOD;Iguratimod >iguratimod( R&D);IguratiMod (T 614);Iguratimod USP/EP/BP;Iguratimod (intermediates I4,I6);N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide
- CBNumber:
- CB91011295
- Molecular Formula:
- C17H14N2O6S
- Molecular Weight:
- 374.37
- MOL File:
- 123663-49-0.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/6/7 16:07:22
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H361 |
| Precautionary statements | P501-P202-P201-P280-P308+P313-P405 |
| HS Code | 2935.90.9500 |
Iguratimod price More Price(4)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML1898 | Iguratimod ≥98% (HPLC) | 123663-49-0 | 5MG | ₹10619.33 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML1898 | Iguratimod ≥98% (HPLC) | 123663-49-0 | 25MG | ₹42877.83 | 2022-06-14 | Buy |
| TCI Chemicals (India) | I0945 | Iguratimod | 123663-49-0 | 25MG | ₹3500 | 2022-05-26 | Buy |
| TCI Chemicals (India) | I0945 | Iguratimod | 123663-49-0 | 250MG | ₹14800 | 2022-05-26 | Buy |
Iguratimod Chemical Properties,Uses,Production
Description
In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.
Uses
Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.
Clinical Use
Iguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29, 2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by Simcere Pharmaceutical Group and is marked as Iremod® in China. The drug exhibited inhibitory effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint destruction in adjuvant arthritis.
Iguratimod Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| GLR Innovations | +91 9891111994 | New Delhi, India | 4542 | 58 | Inquiry |
| Vision Drugs Pvt Ltd | +91 9948045450 | Telangana, India | 65 | 58 | Inquiry |
| Honour Lab Limited | +919845977466 | Telangana, India | 164 | 58 | Inquiry |
| Allastir Private Limited | +91-9840051621 +91-9791039207 | Tamil Nadu, India | 15 | 58 | Inquiry |
| Flax Laboratories | +91-9867665132 +91-9867665132 | Maharashtra, India | 44 | 58 | Inquiry |
| Lewens Labs | +917043057100 | Gujarat, India | 30 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| Archerchem Healthcare Pvt., Ltd. (part of Archerchem Group) | 91-22-42361111 | Maharashtra, India | 147 | 58 | Inquiry |
| Dikora Bulk Drug Pvt. Ltd. | 91-9834786897 | Maharashtra, India | 8 | 58 | Inquiry |
123663-49-0(Iguratimod)Related Search:
1of4
chevron_right